- Home
- FDMT
as 09-12-2025 4:00pm EST
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 192.2M | IPO Year: | 2020 |
| Target Price: | $30.63 | AVG Volume (30 days): | 643.1K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $17.41 | Next Earning Date: | 11-12-2025 |
| Revenue: | $33,000 | Revenue Growth: | -99.84% |
| Revenue Growth (this year): | 8572.97% | Revenue Growth (next year): | -5.73% |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
4DMT Announces New Employment Inducement Grants
GlobeNewswire
4 months ago
4DMT to Participate in Upcoming Investor Conferences
Simply Wall St.
4 months ago
Spotlight On 3 Penny Stocks With Market Caps Under $500M
GlobeNewswire
4 months ago
4DMT Announces New Employment Inducement Grants
MT Newswires
4 months ago
Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating
MT Newswires
4 months ago
RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk
Zacks
4 months ago
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
4 months ago
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.